Related Experiment Videos

Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds

K A Dzenko1, R B Weltzien, J S Pachter

  • 1Department of Pharmacology, University of Connecticut Health Center, Farmington 06030, USA.

Journal of Neuroimmunology
|December 31, 1997
PubMed

Insights

Prior exposure to beta-amyloid (A beta) activates monocytes, causing neurotoxicity. Anti-inflammatory drugs like indomethacin, dexamethasone, and colchicine inhibit this A beta-induced neurotoxicity, suggesting a therapeutic approach for Alzheimer disease (AD).

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Alzheimer disease (AD) is characterized by amyloid plaques.
  • Peripheral blood monocytes (PBM) exposed to aggregated beta-amyloid (A beta) become neurotoxic.
  • This neurotoxicity occurs when PBM are co-cultured with brain tissue.

Purpose of the Study:

  • To investigate the neurotoxic potential of A beta-activated PBM.
  • To determine if anti-inflammatory drugs can inhibit A beta-induced PBM neurotoxicity.
  • To identify the role of soluble factors in mediating A beta-induced PBM neurotoxicity.

Main Methods:

  • Co-culture of PBM with brain tissue after A beta exposure.
  • Treatment of A beta-stimulated PBM with indomethacin, dexamethasone, and colchicine.
  • Analysis of soluble factors released from A beta-stimulated PBM.

Main Results:

  • A beta-exposed PBM induced neurotoxicity in co-cultured brain tissue.
  • Indomethacin, dexamethasone, and colchicine significantly inhibited A beta-induced PBM neurotoxicity.
  • Soluble factors released from A beta-stimulated PBM were largely responsible for the observed neurotoxicity.

Conclusions:

  • A beta-activated PBM contribute to neurotoxicity relevant to Alzheimer disease.
  • Clinically used anti-inflammatory drugs demonstrate potential for treating AD.
  • Targeting soluble factors from activated PBM may offer a therapeutic strategy for AD.

Related Concept Videos